Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 32%
Sell 0%
Strong Sell 5%

Bulls say

Arvinas Inc demonstrates a promising outlook owing to the superior efficacy and safety profile of its product candidates, particularly ARV-806, which exhibits over 40 times greater potency in reducing KRAS G12D protein compared to competitive degraders. This enhanced pharmacological advantage signifies the potential for ARV-806, alongside the company's other candidates, to outperform existing therapies in terms of both efficacy and safety, particularly in combative regimes targeting KRAS mutations. Furthermore, the anticipation of regulatory approval by June 5, 2025, reinforces confidence in the company's innovative approach and its ability to penetrate the market effectively, despite conservative estimates on commercial uptake.

Bears say

Arvinas Inc faces a challenging outlook primarily due to its inability to maintain competitive therapeutic efficacy, as evidenced by the decline in objective response rates (ORR) for its products, with notable reductions in revenue projections for key therapies. Additionally, the company is experiencing difficulties in accessing capital, which could hinder critical business operations and delay its journey towards profitability. Furthermore, the substantial decrease in peak revenue forecasts, particularly for vepdeg, highlights ongoing market uncertainties and the potential erosion of market share.

Arvinas Inc (ARVN) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 32% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 19 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.